Kinoprilam Comp

Hydrochlorothiazide and Quinapril, the active ingredients in Kinoprilam Comp, are an ACE inhibitor and a thiazide diuretic presented as an oral tablet for systemic use. They are indicated for the management of high blood pressure in adult patients, helping to lower cardiovascular risk. Together, they provide complementary mechanisms that enhance blood pressure control.

GNH USA supplies Kinoprilam Comp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Kinoprilam Comp, containing quinapril and hydrochlorothiazide, acts on the renin‑angiotensin system and renal sodium handling to manage conditions characterized by elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure by reducing vascular resistance through ACE inhibition and decreasing plasma volume via diuresis. - Congestive heart failure: assists in decreasing preload and afterload, supporting cardiac function and reducing symptoms of fluid overload. - Edema: promotes renal excretion of sodium and water, helping to reduce peripheral swelling associated with fluid retention.

The combination of quinapril and hydrochlorothiazide may be associated with a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Cough, a dry or tickling sensation in the throat. - Headache. - Increased urination or thirst. - Electrolyte disturbances such as low potassium. - Fatigue.

Serious or Rare Side Effects: - Angio‑edema affecting the face, lips, tongue or airway. - Severe hypotension leading to fainting. - Acute kidney injury or worsening renal function. - Hyperkalemia, especially when combined with potassium‑sparing agents. - Blood disorders such as neutropenia or agranulocytosis. - Severe skin reactions like Stevens‑Johnson syndrome.

Before initiating Kinoprilam Comp, several safety considerations should be reviewed.

- Renal function: assess baseline creatinine and eGFR, adjust if impairment is present. - Electrolytes: monitor potassium and sodium levels, especially in patients on other diuretics. - Pregnancy: avoid use unless clearly needed, as ACE inhibitors are contraindicated in the second and third trimesters. - Concomitant medications: review for drugs that may increase risk of hyperkalemia or renal dysfunction. - Hypotension risk: caution in volume‑depleted patients or those starting therapy. - Store at room temperature: keep the tablets in the original container, protect from moisture and light.

Quinapril and hydrochlorothiazide can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aliskiren: combined use with ACE inhibitors may increase risk of renal impairment and hyperkalemia. - Lithium: ACE inhibition can raise lithium levels, risking toxicity. - NSAIDs: may reduce antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia. - Other antihypertensives: additive blood‑pressure‑lowering effect may cause hypotension. - Antidiabetic agents: thiazides can affect glucose control, requiring dose adjustment.